What is ABPRO HLDGS INC's earnings per share (EPS)?

ABPRO HLDGS INC (ABP) reported diluted earnings per share of $-1.30 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ABPRO HLDGS INC Financials

ABP

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows ABPRO HLDGS INC (ABP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ABP FY2025 2026-05-20

Abpro’s filings describe a development-stage business sustained mainly by external financing as liquidity keeps tightening.

From FY2024 to FY2025, net loss narrowed from -$7.2M to -$2.9M, but liquidity deteriorated: cash fell from $2.9M to $82K and the current ratio slipped from 0.2x to 0.1x. Paired with R&D spending dropping from $3.0M to $989K, the smaller loss looks more like a reduced operating footprint than a business that has started funding itself.

Balance-sheet pressure is the central operating constraint: FY2025 ended with $1.1M of assets against $9.9M of liabilities and negative equity of -$8.8M. With current assets of $896K covering only a small fraction of current liabilities of $9.3M, near-term obligations dominate the financial picture far more than reported sales or margins do.

FY2023’s positive net income of $2.8M did not translate into cash, because operating cash flow was -$7.4M and free cash flow was -$7.5M. That gap, followed by another -$9.0M of operating cash outflow in FY2024, shows earnings quality was weak and financing, not operations, supplied liquidity.

Financial Health Signals

Financial health score pending refresh

We are recalculating ABPRO HLDGS INC's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$2.9M

YoY+60.0%

ABPRO HLDGS INC reported -$2.9M in net income in fiscal year 2025. This represents an increase of 60.0% from the prior year.

EPS (Diluted)

$-1.30

ABPRO HLDGS INC earned $-1.30 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$82K

YoY-97.1%

ABPRO HLDGS INC held $82K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

ABPRO HLDGS INC had 3M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$989K

YoY-66.8%

ABPRO HLDGS INC invested $989K in research and development in fiscal year 2025. This represents a decrease of 66.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ABP Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	N/A	$183K+50.0%	$122K	N/A
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	$989K-66.8%	$3.0M-30.1%	$4.3M	N/A
SG&A Expenses	N/A	$7.1M-6.3%	$7.6M	N/A
Operating Income	N/A	-$9.9M+15.5%	-$11.7M-472.9%	-$2.1M
Interest Expense	$1.1M+191.5%	$387K+1582.6%	$23K	N/A
Income Tax	N/A	N/A	$1.2M+42.9%	$824K
Net Income	-$2.9M+60.0%	-$7.2M-356.3%	$2.8M+218.1%	$887K
EPS (Diluted)	$-1.30	$-22.31-3557.4%	$-0.61	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$13K	N/A	$243K-22.4%	$313K-3.7%	$325K	N/A	$642K-22.4%	$827K
SG&A Expenses	$920K	N/A	$1.1M-43.9%	$1.9M-26.0%	$2.6M	N/A	$1.5M-2.7%	$1.5M
Operating Income	-$933K	N/A	-$1.3M+40.9%	-$2.3M+23.6%	-$3.0M	N/A	-$1.9M+17.5%	-$2.3M
Interest Expense	$23K	N/A	$193K+10.9%	$174K-76.4%	$737K	N/A	$164K+62.4%	$101K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	$28K+5.7%	$26K
Net Income	-$1.0M	N/A	-$1.7M+44.5%	-$3.0M+23.2%	-$3.9M	N/A	-$335K+1.1%	-$339K
EPS (Diluted)	$-0.23	N/A	$-0.63	$-0.05+97.8%	$-2.29	N/A	$-3.27-2415.4%	$-0.13

ABP Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$1.1M-77.2%	$4.7M+38.9%	$3.4M-98.9%	$310.6M
Current Assets	$896K-76.3%	$3.8M+85.6%	$2.0M+164.2%	$770K
Cash & Equivalents	$82K-97.1%	$2.9M+294.2%	$723K+84.2%	$392K
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	$183K0.0%	$183K+108.0%	$88K	N/A
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$9.9M-49.5%	$19.6M-78.8%	$92.3M-71.3%	$321.7M
Current Liabilities	$9.3M-52.3%	$19.6M+24.6%	$15.7M+634.6%	$2.1M
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	-$8.8M+43.0%	-$15.5M+82.6%	-$89.0M-696.0%	-$11.2M
Retained Earnings	-$119.0M-2.5%	-$116.1M-6.6%	-$108.9M-12.0%	-$97.2M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$6.9M+545.8%	$1.1M-37.6%	$1.7M-51.1%	$3.5M+24.5%	$2.8M-40.0%	$4.7M-40.7%	$7.9M-0.5%	$7.9M
Current Assets	$6.7M+647.9%	$896K-26.9%	$1.2M-60.1%	$3.1M+38.3%	$2.2M-41.2%	$3.8M+142.0%	$1.6M+462.8%	$277K
Cash & Equivalents	$5.4M+6501.2%	$82K-76.1%	$343K-83.1%	$2.0M+44.4%	$1.4M-50.7%	$2.9M+20860.5%	$14K-94.3%	$237K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$183K0.0%	$183K-32.5%	$271K-20.8%	$342K+3.3%	$331K+80.9%	$183K	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$9.7M-2.3%	$9.9M-44.6%	$17.8M-14.9%	$21.0M-0.8%	$21.2M+7.9%	$19.6M-23.6%	$25.7M+1.5%	$25.3M
Current Liabilities	$9.1M-2.4%	$9.3M-46.0%	$17.3M-15.3%	$20.4M-0.9%	$20.6M+5.1%	$19.6M+116.9%	$9.0M+23.7%	$7.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.8M+68.3%	-$8.8M+45.3%	-$16.1M+7.7%	-$17.5M+4.7%	-$18.4M-18.5%	-$15.5M+13.0%	-$17.8M-2.4%	-$17.4M
Retained Earnings	-$120.0M-0.9%	-$119.0M+4.5%	-$124.6M-1.3%	-$123.0M-2.5%	-$120.0M-3.3%	-$116.1M-3.0%	-$112.8M-548.2%	-$17.4M

ABP Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	N/A	-$9.0M-22.0%	-$7.4M-524.7%	-$1.2M
Capital Expenditures	N/A	N/A	$48K	N/A
Free Cash Flow	N/A	N/A	-$7.5M	N/A
Investing Cash Flow	N/A	N/A	N/A	-$305.7M
Financing Cash Flow	$3.1M-72.5%	$11.2M+1214.6%	$849K-99.7%	$307.2M
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$0

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$2.1M-235.5%	-$620K+72.8%	-$2.3M-42.4%	-$1.6M-6.6%	-$1.5M+60.6%	-$3.8M-282.6%	-$997K+27.2%	-$1.4M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$20K+33.3%	-$30K
Financing Cash Flow	$7.4M+1964.3%	$359K-36.9%	$569K-74.4%	$2.2M+2750.0%	-$84K-101.3%	$6.7M+612.2%	$936K-22.9%	$1.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0

ABP Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	-5421.3%+4206.6pp	-9627.9%	N/A
Net Margin	N/A	-3951.9%-6264.6pp	2312.7%	N/A
Return on Equity	N/A	N/A	N/A	N/A
Return on Assets	-272.1%-116.9pp	-155.2%-239.3pp	84.1%+83.8pp	0.3%
Current Ratio	0.10-0.1	0.19+0.1	0.13-0.2	0.36
Debt-to-Equity	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	-6106.6%	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-15.0%	N/A	-97.3%-11.6pp	-85.7%+53.3pp	-139.0%	N/A	-4.3%+0.0pp	-4.3%
Current Ratio	0.73+0.6	0.10+0.0	0.07-0.1	0.15+0.0	0.11-0.1	0.19+0.0	0.17+0.1	0.04
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$8.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.10), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Biomx Inc PHGE

$2.0M

Adaptimmune Therapeutics Plc ADAP

$14.6M

APOLLOMICS INC APLM

$38.1M

Phio Pharmaceuticals Corp PHIO

$12.0M

Biocardia Inc BCDA

$11.5M

Frequently Asked Questions

Is ABPRO HLDGS INC profitable?

No, ABPRO HLDGS INC (ABP) reported a net income of -$2.9M in fiscal year 2025.

What are ABPRO HLDGS INC's total assets?

ABPRO HLDGS INC (ABP) had $1.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does ABPRO HLDGS INC spend on research and development?

ABPRO HLDGS INC (ABP) invested $989K in research and development during fiscal year 2025.

How many shares does ABPRO HLDGS INC have outstanding?

ABPRO HLDGS INC (ABP) had 3M shares outstanding as of fiscal year 2025.

What is ABPRO HLDGS INC's current ratio?

ABPRO HLDGS INC (ABP) had a current ratio of 0.10 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is ABPRO HLDGS INC's return on assets (ROA)?

ABPRO HLDGS INC (ABP) had a return on assets of -272.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Why is ABPRO HLDGS INC's debt-to-equity ratio negative or not reported?

ABPRO HLDGS INC (ABP) has negative shareholder equity of -$8.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.